Treatment Prevalence Project

Background information

Expert meetingImplementation of the treatment strategy –

Module 1: TDI prevalence 24 June 2013

Aim of the project

• To have the total number of treatment clients in a country

• To collect data on the total number of drug addicts reached by treatment

• To get the number of drug users in treatment for long period or more than one year

• To have a picture of the profile of the treated population, including its characteristics

History of the project (1)

• May 2005: proposal of the Dutch SC member

• September 2005: discussion during the TDI expert meeting, NL presentation and setting up a working

group

• November 2005: proposal for a pilot project presented to NFPs

• January 2006: working group meeting 9 volunteer countries and launch of pilot project

• Summer 2006: 1st pilot data collection

• Sep.-Nov. 2006 presentations first results during the TDI and RTX meeting

History of the project (2)

• Summer 2007: 2nd pilot data collection

• Summer 2007: feasibility assessment with NFPs

• Sep.-Nov.2007: presentations results of 2nd pilot data collection and of the feasibility assessment (TDI and

RTX meeting)

• 2008: 3rd pilot data collection

• 2008 until 2012:TDI revision: TDI prevalence as separated project

• 2013: TDI prevalence included in the 2013 Work programme

Results from feasibility assessment (2007) 28 countries replied: 25 MS + TK + HR + NO

2 countries not replying: RO, SI

24

4

0

15

8

5

0

5

10

15

20

25

30

Already collectin Planning to collect Not planning to collect

TDI TR. Prevalence

Source: Results from a survey to the NFPs on feasibility assessment

Reasons for collecting prevalence data(23 countries)

• More complete information on the whole drug problem

• Overview of drug treatment population: most part of treatment clients is not included in the current TDI data collection

• More “realistic” picture on the number of drug clients

• Useful data for treatment planning: it gives information on treatment capacities and treatment needs

• Increase research and analysis potentialities with TDI data

Reasons for not collecting prevalence data(5 countries – DK, SP, GR, SW, NO)

• Data collection: low feasibility (3 countries) or not feasible (2 countries)

• Burden increase in the NFPs and treatment networks

• Decrease in data quality

• 50% increase in financial (between 20.000 and 300.000 euros) and human resources (between 3 and 5 staff members) in the implementation phase

• Less for maintaining the information system

• Not much added value to the information currently collected

Resources to be invested

• No additional costs for 7 countries

• Differences in the remaining countries

• Human resources: between 1 and 8 staff

• Financial resources: between 20 000 and 100 000 Euros (often including staff cost)

Additional feedback from NFPs and TDI experts

• Agreement on implementing data collection on treatment prevalence

• Clear definition/methodology needed

• Only basic data should be collected